# Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Source: https://onco.cc/trials/nct00539591/  
OnCo record `nct00539591` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Peginterferon alfa-2b and Temozolomide in Melanoma, run by St. Jude Children's Research Hospital, active and no longer recruiting.

## Summary

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma is a phase 2 interventional study registered as NCT00539591 by St. Jude Children's Research Hospital, with 29 participants planned, started 2008-05-09 and due to reach its primary completion in 2015-06. Interventions recorded: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b. Conditions recorded: Malignant Melanoma.

Linked to the drug Peginterferon alfa-2b because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00539591
- Phase: 2
- Setting: Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
- Sponsor: St. Jude Children's Research Hospital
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT00539591: https://clinicaltrials.gov/study/NCT00539591

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Peginterferon alfa-2b](https://onco.cc/drugs/peginterferon-alfa-2b/), [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct00539591.json